Bharat Biotech Gets Shot In Arm With 81% Efficacy For COVID-19 Vaccine
Higher Than Comparable, Approved Vaccines
Bharat Biotech’s COVID-19 vaccine has shown 80.6% efficacy in interim data from Phase III clinical trials, slightly better than the 79.3% reported by Sinopharm and significantly higher than Sinovac’s 50.6% for their vaccines based on similar technology. Supply deals are already on the way, with Brazil having signed up for 200 million doses.
You may also be interested in...
A COVID-19 vaccine alliance between US, Japan, India and Australia announced funding for Johnson & Johnson’s vaccine made by Biological E. Will the arrangement be extended to other vaccines and will the alliance push US to address materials export concerns, recently raised by Serum Institute?
More Encouraging Real World Data From UK – But Can It Turn Around European Sentiment On AZ COVID-19 Vaccine?
Another real-world study from the UK’s rapid vaccine rollout provides evidence that Pfizer’s vaccine saves lives, with the AZ shot matching it on cutting hospitalizations.
A round up of COVID-19 developments, including the CDC advising that it is "prudent" to start testing variant vaccines in case the South African B.1.351 strain gains a foothold in the US.